Is Novartis AG (NVS) a Buy, Sell, or Hold?
NYSE : NVS
Novartis AG
$156.11 USD
$1.1 (0.71%)
- Volume
- 1.62M
- Average Volume
- 1.82M
- Market Capitalization
- $296.72B
- P/E Ratio
- 23.81
- Dividend Yield
- 2.88%
- Price Target
- $170.00
- Year High
- $170.46
- Year Low
- $112.34
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.68
- Current Ratio
- $0.86
Company Overview
NYSE
Vas Narasimhan
Drug Manufacturers - General
Healthcare
NVS
75267
CH
USD
Liquidity Metrics
1.18
0.86
0.67
0.24
0.68
Sales & Valuation
$54.81B
5.44
7.18
18.67
8.38
Profitability
$7.19
$14.06B
23.09%
28.09%
29.64%
10.34%
P/E Metrics
23.81
-5.30
-5.30
Analyst Price Target & Rating
$170.00
$170.00
$170.00
3/5
25 Analysts
-8.17%
Financial Health Scores
3.53
6/9
-$4.4B
$122.03B
$80.09B
$16.92B
Key Metrics (TTM)
$340.83B
6.22
15.46
0.86
29.64%
13.38%
4.22%
5.34%
$57.16
117 days
Company Executives
| Name | Title |
|---|---|
| Steffen Lang | President of Operations |
| Vasant Narasimhan | Chief Executive Officer |
| Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research |
| Mukul Mehta | Chief Financial Officer |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Sloan Simpson | Global Head of Investor Relations |
| Victor Bulto | President of US |
| Karen L. Hale | Chief Legal & Compliance Officer |
| Robert Kowalski | Chief People & Organization Officer |
| Patrick Horber | President of International |
Poll Results
No votes yet today — be the first to share your view!
About Novartis AG (NYSE:NVS) Stock
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland. ...
12,359 Shares in Novartis AG $NVS Bought by Entropy Technologies LP
2026-07-27 05:05:07
Entropy Technologies LP acquired a new position in shares of Novartis AG (NYSE: NVS) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 12,359 shares of the company's stock, valued at approximately $1,888,000. A number of other large
Cetera Investment Advisers Buys 24,096 Shares of Novartis AG $NVS
2026-07-27 04:18:59
Cetera Investment Advisers grew its position in shares of Novartis AG (NYSE: NVS) by 13.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 203,045 shares of the company's stock after acquiring an additional 24,096 shares during the quarter.
Novartis: The Buy Thesis Is Back (Rating Upgrade)
2026-07-22 09:28:33
Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine, the performance of its oncology franchise was remarkably strong. So, sales of Pluvicto, a medication used to treat PSMA-positive metastatic castration-resistant prostate cancer, were $651 million in Q2, up 43.4% year-on-year.
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
2026-07-21 17:43:56
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis CEO on 2Q Profit Beat, Investing in Pipeline
2026-07-21 17:16:29
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug Entresto. CEO Vas Narasimhan discussed the company's strategic focus on navigating significant patent expiries in the first half of the year, followed by a growth phase in the second half fueled by investments in the pipeline and new product launches.
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
2026-07-21 12:46:10
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
Q2 Earnings Pick Up Steam: GM, MMM, DHI & More
2026-07-21 11:50:35
GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning.
Novartis Q2 Earnings Call Highlights
2026-07-21 11:07:39
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto.
Frequently Asked Questions
-
What is the current Novartis AG (NVS) stock price?
-
Novartis AG(NYSE:NVS) stock price is $156.11 in the last trading session. During the trading session, NVS stock reached the peak price of $170.46 while $112.34 was the lowest point it dropped to. The percentage change in NVS stock occurred in the recent session was 0.71% while the dollar amount for the price change in NVS stock was $1.1.
-
NVS's industry and sector of operation?
-
The NYSE listed NVS is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of NVS?
-
Steffen Lang | President of Operations
Vasant Narasimhan | Chief Executive Officer
Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research
Mukul Mehta | Chief Financial Officer
Paul Penepent | Head of Group Financial Reporting and Accounting -
How many employees does NVS have?
-
Number of NVS employees currently stands at 75267. NVS operates from Lichtstrasse 35, Basel, BS 4056, CH.
-
Link for NVS official website?
-
Official Website of NVS is: https://www.novartis.com
-
How do I contact NVS?
-
NVS could be contacted at phone #41 61 324 1111 and can also be accessed through its website. NVS operates from Lichtstrasse 35, Basel, BS 4056, CH.
-
How many shares of NVS are traded daily?
-
The average number of NVS shares traded daily for last 3 months was 1.82M.
-
What is the market cap of NVS currently?
-
The market value of NVS currently stands at $296.72B with its latest stock price at $156.11